Amryt Pharma PLC - biopharmaceutical company - Increases full year revenue guidance to between USD210 and USD215 million, representing growth of 15% to 18% on 2020. Previous guidance issued in May was revenue between USD205 million and USD210 million. Second quarter revenue rises USD62.8 million, 36% higher than a year previously and 30% above the first quarter. The revenue rise is attributed to products such as Metreleptin and Lomitapide, which continue to deliver solid sales growth.
For the six months to June Amryt narrows its pretax loss to USD22.5 million from USD52.1 million a year previously.
"These results demonstrate the positive momentum and strong growth we are experiencing across our business, supported by our exceptional team who during the quarter delivered several important commercial and regulatory successes," comments Chief Executive Joe Wiley.
Current stock price: 154.00 pence, up 2.7% on Friday
Year-to-date change: down 18%
By Will Paige; willpaige@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
